S-100 protein antibody(Materia Medica Holding)(S-100 protein antibody(Materia Medica Holding))

概要

基本信息

药物类型

单克隆抗体

别名

Tenoten

靶点-

作用机制-

治疗领域

其他疾病

在研适应症

焦虑症

非在研适应症

脑损伤学习障碍

原研机构

OOO NPF Materia Medica Holding

在研机构

OOO NPF Materia Medica Holding

非在研机构-

最高研发阶段批准上市

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

3

项与 S-100 protein antibody(Materia Medica Holding) 相关的临床试验

NCT03036293 / Completed临床4期

International Multicenter, Double-blind, Randomized Placebo-controlled Phase IV Clinical Trial of Different Dosing Regimens of Tenoten® in the Treatment of Anxiety in Patients With Somatoform, Stress-related and Other Neurotic Disorders

The purposes of this study are:
To further examine the efficacy and safety of Tenoten® in the treatment of anxiety in patients with somatoform, stress-related and other neurotic disorders.
To compare the efficacy of two dosing regimens of Tenoten® (4 tablets daily vs.8 tablets daily, both for 12 weeks) in the treatment of anxiety in patients with somatoform, stress-related and other neurotic disorders.

开始日期2017-02-08

申办/合作机构

OOO NPF Materia Medica Holding

NCT03159611 / Completed临床3期

Multicenter Double-blind Placebo-controlled Parallel-group Randomized Clinical Trial of Efficacy and Safety of Tenoten for Children Liquid Dosage Form Therapy in Infants With Sequelae of Perinatal Brain Injury

Purpose of the study:
To assess the clinical efficacy of Tenoten for children liquid dosage form therapy (10 oral drops per day for 12 weeks) in Infants with Sequelae of Perinatal Brain Injury (mild-to-moderate cerebral hypoxia-ischaemia and/or mild-to-moderate intracranial haemorrhage).
To assess the safety of Tenoten for children liquid dosage form therapy (10 oral drops per day for 12 weeks) in Infants with Sequelae of Perinatal Brain Injury (mild-to-moderate cerebral hypoxia-ischaemia and/or mild-to-moderate intracranial haemorrhage).

开始日期2016-02-19

申办/合作机构

OOO NPF Materia Medica Holding

NCT03159104 / Completed临床3期

Multicenter Double-blind Placebo-Controlled Randomized Clinical Trial of Efficacy and Safety of Tenoten for Children in the Treatment of Specific Developmental Disorders of Scholastic Skills in Children

Purpose of the study:
• To evaluate efficacy and safety of Tenoten for children in the treatment of specific developmental disorders of scholastic skills in children.

开始日期2015-08-25

申办/合作机构

OOO NPF Materia Medica Holding

100 项与 S-100 protein antibody(Materia Medica Holding) 相关的临床结果

登录后查看更多信息

100 项与 S-100 protein antibody(Materia Medica Holding) 相关的转化医学

登录后查看更多信息

100 项与 S-100 protein antibody(Materia Medica Holding) 相关的专利（医药）

登录后查看更多信息

67

项与 S-100 protein antibody(Materia Medica Holding) 相关的文献（医药）

2024-01-23·Blood Advances

Protein S antibody as an adjunct therapy for hemophilia B

Article

作者: Chatterjee, Sabyasachi ; Velez, Maria C. ; Janbain, Maissaa ; Pierre, Aliyah ; Majumder, Rinku ; Dorsey, Adrianne W. ; Polania-Villanueva, Diana ; Paysse, Ashley L. ; Kumar, Narender ; Rudra, Pratyadipta ; Wilson, Hope P. ; Cooley, Brian C.

AbstractHemophilia B (HB) is caused by an inherited deficiency of plasma coagulation factor IX (FIX). Approximately 60% of pediatric patients with HB possess a severe form of FIX deficiency (<1% FIX activity). Treatment typically requires replacement therapy through the administration of FIX. However, exogenous FIX has a limited functional half-life, and the natural anticoagulant protein S (PS) inhibits activated FIX (FIXa). PS ultimately limits thrombin formation, which limits plasma coagulation. This regulation of FIXa activity by PS led us to test whether inhibiting PS would extend the functional half-life of FIX and thereby prolong FIX-based HB therapy. We assayed clotting times and thrombin generation to measure the efficacy of a PS antibody for increasing FIX activity in commercially obtained plasma and plasma from pediatric patients with HB. We included 11 pediatric patients who lacked additional comorbidities and coagulopathies. In vivo, we assessed thrombus formation in HB mice in the presence of the FIXa ± PS antibody. We found an accelerated rate of clotting in the presence of PS antibody. Similarly, the peak thrombin formed was significantly greater in the presence of the PS antibody, even in plasma from patients with severe HB. Furthermore, HB mice injected with PS antibody and FIX had a 4.5-fold higher accumulation of fibrin at the thrombus induction site compared with mice injected with FIX alone. Our findings imply that a PS antibody would be a valuable adjunct to increase the effectiveness of FIX replacement therapy in pediatric patients who have mild, moderate, and severe HB.

2024-01-01·S.S. Korsakov Journal of Neurology and Psychiatry

Anxiety disorders as comorbid conditions in neuropsychiatric diseases in children

Review

作者: Zavadenko, N N ; Zavadenko, A N ; Shypilova, E M ; Nesterovskiy, Yu E

The variants of heterotypic comorbidity of anxiety disorders (AD) with attention deficit hyperactivity disorder, autism spectrum disorders, speech and language development disorders, specific learning disabilities (dyslexia, dysgraphia, dyscalculia), migraine, tension type headache in children and adolescents are discussed. In cases of heterotypic comorbidity the patients with AD referrals to specialists may be primarily associated with their emotional problems. Meanwhile, the comorbidity of AD with these diseases leads to a deterioration of their clinical manifestations and a worsening of the prognosis, and anxiety symptoms often not only persist, but also increase with age. It should be borne in mind that AD in children with neurodevelopmental disorders contribute to a decrease in the quality of life, academic failure, have a negative impact on peer relationships and the family environment, and in young adulthood, patients have an increased risk of depression and substance abuse. Therefore, early intervention and a comprehensive therapeutic approach with a dynamic assessment of the patient's condition are becoming important. When choosing pharmacotherapy, it is advisable to choose medictions that have a complex effect on the pathogenetic mechanisms of the underlying disease and concomitant AD, which include Tenoten for children.

2021-01-01·Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova

Neurodevelopmental disorders in children and the possibilities of their pharmacotherapy

Article

作者: Fateeva, V V ; Zavadenko, N N ; Zavadenko, A N ; Suvorinova, N Yu

Neurodevelopmental disorders (NDD) are characterized by disturbances of the formation of cognitive functions, communication skills, behavior characteristics and/or motor skills, which are caused by abnormalities in the course of the processes of neuroontogenesis. In the clinical practice of a pediatric neurologist and pediatrician, a significant part consists of patients with NDD without a general decrease in intelligence, primarily with speech development disorders, attention deficit hyperactivity disorder (ADHD), specific learning disorders (dyslexia, dysgraphia, dyscalculia). NDD represent a heterogeneous group of diseases, having multifactorial origin and a neurobiological nature, which are caused by genetic mechanisms and early (perinatal) brain damage. Among children with NDD, there is a higher occurrence of anxiety disorders compared to their peers. With NDD, early intervention is indicated, and its positive effect is possible during the period when the brain is most plastic and capable of changes. The published results of multicenter, double-blind, placebo-controlled, randomized clinical trials of pharmacotherapy with the medication "Tenoten for children" for ADHD, specific learning disorders, anxiety disorders and the consequences of perinatal damage to the central nervous system are reviewed.

100 项与 S-100 protein antibody(Materia Medica Holding) 相关的药物交易

登录后查看更多信息

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
焦虑症	俄罗斯	OOO NPF Materia Medica Holding	-

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
脑损伤	药物发现	俄罗斯	OOO NPF Materia Medica Holding	2016-02-19
学习障碍	药物发现	俄罗斯	OOO NPF Materia Medica Holding	2015-08-25

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03159104 (CTgov)	临床3期	学习障碍	240	Tenoten for children (Tenoten for Children)	糧鑰衊選鹹鬱醖淵願遞(觸鹹遞鏇簾壓鹽餘醖觸) = 鏇壓淵廠蓋積積範鏇選選廠齋觸鑰製膚醖襯鹽 (製網鹽簾齋築醖遞衊廠, 鹽糧鏇製艱鏇範蓋襯廠 ~ 築醖繭蓋獵選鏇蓋憲鑰) 更多	-	2023-08-21
				Placebo (Placebo)	糧鑰衊選鹹鬱醖淵願遞(觸鹹遞鏇簾壓鹽餘醖觸) = 襯鬱獵鹹構糧簾衊範衊選廠齋觸鑰製膚醖襯鹽 (製網鹽簾齋築醖遞衊廠, 繭憲壓艱構構蓋鑰繭蓋 ~ 遞艱鏇顧淵鏇鏇衊廠淵) 更多
NCT03036293 (CTgov)	临床4期	焦虑症	390	Tenoten (Tenoten, 2 Tablets Twice Daily (4 Tablets/Day))	餘鹽廠範鹹顧糧齋繭廠(獵觸鏇夢繭鬱積鏇構淵) = 夢淵鬱鹽顧鏇襯窪夢糧選齋鬱獵窪餘夢鹽襯鬱 (鑰網憲觸憲壓獵遞襯網, 鹽獵醖鏇蓋鬱鹽獵觸鬱 ~ 構構顧衊鹹鏇窪顧襯糧) 更多	-	2020-12-31
				Tenoten (Tenoten, 2 Tablets 4 Times Daily (8 Tablets/Day))	餘鹽廠範鹹顧糧齋繭廠(獵觸鏇夢繭鬱積鏇構淵) = 鹹蓋淵夢膚築衊獵選築選齋鬱獵窪餘夢鹽襯鬱 (鑰網憲觸憲壓獵遞襯網, 鑰淵遞膚製夢遞鹽範膚 ~ 觸構積製夢網廠觸積衊) 更多
NCT03159611 (CTgov)	临床3期	脑损伤	182	Tenoten for children (Tenoten for Children)	築膚顧觸鏇窪襯壓鏇艱(範選選願築願網獵憲膚) = 獵簾鏇繭糧製網蓋範窪壓網窪選積願鹹糧膚夢 (鑰鬱糧獵廠襯觸選鹽憲, 壓鏇獵淵憲夢艱鏇觸鑰 ~ 繭築繭願糧繭鏇襯顧襯) 更多	-	2019-04-08
				Placebo (Placebo)	築膚顧觸鏇窪襯壓鏇艱(範選選願築願網獵憲膚) = 鬱醖淵廠襯憲鏇壓窪繭壓網窪選積願鹹糧膚夢 (鑰鬱糧獵廠襯觸選鹽憲, 顧艱獵觸積觸廠醖鏇鑰 ~ 簾選廠糧鑰蓋選衊遞衊) 更多